Aeglea Appoints Sandy Mahatme And Russell Cox To Board Of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Aeglea Biotherapeutics, Inc., a biopharmaceutical company committed to developing enzyme based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Sandy Mahatme and Russell Cox to its Board of Directors. Mr. Mahatme currently serves as Senior Vice President, Chief Financial Officer for Sarepta Therapeutics, and Mr. Cox serves as Executive Vice President and Chief Operating Officer for Jazz Pharmaceuticals.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.